NuCana plc reported fourth quarter and year-end 2025 financial results, with a Q4 net loss of £2.5 million and full-year net loss of £29.4 million, alongside £24.3 million in cash and cash equivalents expected to fund operations into 2029. The company highlighted clinical activity of NUC-7738 in PD-1 inhibitor-resistant melanoma and outlined 2026 milestones including Phase 2 data and FDA guidance.
Key takeaways
Cash and cash equivalents of £24.3 million as of December 31, 2025, sufficient to fund operations into 2029.
Q4 2025 net loss of £2.5 million vs £0.7 million in Q4 2024; basic and diluted loss per ordinary share £0.00 vs £0.01.
FY 2025 net loss of £29.4 million vs £19.0 million in FY 2024; basic and diluted loss per ordinary share £0.00 vs £0.26.
NUC-7738 showed two partial responses (one confirmed) and stable disease in Phase 2 NuTide:701 study with pembrolizumab in PD-1 resistant melanoma.
Expected to complete enrollment in Phase 2 NuTide:701 expansion study in first half of 2026 with final data later in 2026.
Appointed Theresa Bruce as Chief Operating Officer earlier this year.